Buprenorphine: Dose-related blockade of opioid challenge effects in opioid dependent humans

W. K. Bickel, Maxine L Stitzer, George Bigelow, I. A. Liebson, D. R. Jasinski, R. E. Johnson

Research output: Contribution to journalArticle

Abstract

This study assessed the blockade of hydromorphone challenge effects (cumulative s.c. doses of 0, 6, and 18 mg) during chronic buprenorphine treatment of opioid dependent subjects. Buprenorphine was administered daily via the sublingual route in ascending doses of 2, 4, 8 and 16 mg. Hydromorphone challenges were conducted after 10 to 14 days of chronic administration of each buprenorphine dose and 24 h after the last buprenorphine dose. Buprenorphine itself only produced dose-related effects in respiration rate. While subjects were maintained on 2 mg of buprenorphine, the hydromorphone challenge produced dose-related changes in physiological and self-report measures. As the dose of buprenorphine was increased, hydromorphone effects on self-report measures were attenuated to a greater extent than was noted for pupil diameter. The results of this study confirm previous reports of buprenorphine blockade of opioid agonist effects in humans and extend those findings by demonstrating both a buprenorphine dose-effect function and a dissociation between the potency of buprenoprhine's opioid blockade for self-report vs. physiological measures.

Original languageEnglish (US)
Pages (from-to)47-53
Number of pages7
JournalJournal of Pharmacology and Experimental Therapeutics
Volume247
Issue number1
StatePublished - 1988

Fingerprint

Buprenorphine
Opioid Analgesics
Hydromorphone
Self Report
Pupil
Respiratory Rate

ASJC Scopus subject areas

  • Pharmacology

Cite this

Buprenorphine : Dose-related blockade of opioid challenge effects in opioid dependent humans. / Bickel, W. K.; Stitzer, Maxine L; Bigelow, George; Liebson, I. A.; Jasinski, D. R.; Johnson, R. E.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 247, No. 1, 1988, p. 47-53.

Research output: Contribution to journalArticle

@article{48f9d6609d5f48c7b40e52ff98836fe9,
title = "Buprenorphine: Dose-related blockade of opioid challenge effects in opioid dependent humans",
abstract = "This study assessed the blockade of hydromorphone challenge effects (cumulative s.c. doses of 0, 6, and 18 mg) during chronic buprenorphine treatment of opioid dependent subjects. Buprenorphine was administered daily via the sublingual route in ascending doses of 2, 4, 8 and 16 mg. Hydromorphone challenges were conducted after 10 to 14 days of chronic administration of each buprenorphine dose and 24 h after the last buprenorphine dose. Buprenorphine itself only produced dose-related effects in respiration rate. While subjects were maintained on 2 mg of buprenorphine, the hydromorphone challenge produced dose-related changes in physiological and self-report measures. As the dose of buprenorphine was increased, hydromorphone effects on self-report measures were attenuated to a greater extent than was noted for pupil diameter. The results of this study confirm previous reports of buprenorphine blockade of opioid agonist effects in humans and extend those findings by demonstrating both a buprenorphine dose-effect function and a dissociation between the potency of buprenoprhine's opioid blockade for self-report vs. physiological measures.",
author = "Bickel, {W. K.} and Stitzer, {Maxine L} and George Bigelow and Liebson, {I. A.} and Jasinski, {D. R.} and Johnson, {R. E.}",
year = "1988",
language = "English (US)",
volume = "247",
pages = "47--53",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - Buprenorphine

T2 - Dose-related blockade of opioid challenge effects in opioid dependent humans

AU - Bickel, W. K.

AU - Stitzer, Maxine L

AU - Bigelow, George

AU - Liebson, I. A.

AU - Jasinski, D. R.

AU - Johnson, R. E.

PY - 1988

Y1 - 1988

N2 - This study assessed the blockade of hydromorphone challenge effects (cumulative s.c. doses of 0, 6, and 18 mg) during chronic buprenorphine treatment of opioid dependent subjects. Buprenorphine was administered daily via the sublingual route in ascending doses of 2, 4, 8 and 16 mg. Hydromorphone challenges were conducted after 10 to 14 days of chronic administration of each buprenorphine dose and 24 h after the last buprenorphine dose. Buprenorphine itself only produced dose-related effects in respiration rate. While subjects were maintained on 2 mg of buprenorphine, the hydromorphone challenge produced dose-related changes in physiological and self-report measures. As the dose of buprenorphine was increased, hydromorphone effects on self-report measures were attenuated to a greater extent than was noted for pupil diameter. The results of this study confirm previous reports of buprenorphine blockade of opioid agonist effects in humans and extend those findings by demonstrating both a buprenorphine dose-effect function and a dissociation between the potency of buprenoprhine's opioid blockade for self-report vs. physiological measures.

AB - This study assessed the blockade of hydromorphone challenge effects (cumulative s.c. doses of 0, 6, and 18 mg) during chronic buprenorphine treatment of opioid dependent subjects. Buprenorphine was administered daily via the sublingual route in ascending doses of 2, 4, 8 and 16 mg. Hydromorphone challenges were conducted after 10 to 14 days of chronic administration of each buprenorphine dose and 24 h after the last buprenorphine dose. Buprenorphine itself only produced dose-related effects in respiration rate. While subjects were maintained on 2 mg of buprenorphine, the hydromorphone challenge produced dose-related changes in physiological and self-report measures. As the dose of buprenorphine was increased, hydromorphone effects on self-report measures were attenuated to a greater extent than was noted for pupil diameter. The results of this study confirm previous reports of buprenorphine blockade of opioid agonist effects in humans and extend those findings by demonstrating both a buprenorphine dose-effect function and a dissociation between the potency of buprenoprhine's opioid blockade for self-report vs. physiological measures.

UR - http://www.scopus.com/inward/record.url?scp=0023770034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023770034&partnerID=8YFLogxK

M3 - Article

C2 - 2459370

AN - SCOPUS:0023770034

VL - 247

SP - 47

EP - 53

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 1

ER -